Bristol's Oncology Strategy: Cover All The Bases To Keep The Lead
Bristol stresses comprehensive approach to lung cancer – its top priority – with trials from early to late stages, a thoughtful biomarker development program and a pipeline stocked with drugs that have a wide range of targets.
You may also be interested in...
Merck's Keytruda gains huge advantage in first-line lung cancer as Bristol's stumble in patients with lower expression of PD-L-1 biomarker raises questions about cut-off levels in trials.
Failure of Bristol's Opdivo in patients with lower expression of PD-L-1 biomarker gives Merck's Keytruda a huge advantage in first-line lung cancer, and leaves market-leading Bristol to wait for combination data.
The nine drug manufacturers with products selected for Medicare drug price negotiations have agreed to participate in the program. Seven of them now have pending suits challenging the Inflation Reduction Act program with Novo’s recent complaint, which objects to the aggregation of its insulin products.